Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Docampo, LCI; Arrula, VA; Rotllan, NB; Maseda, AC; Cirauqui, BC; Escobar, Y; Sorrosal, JJL; Borgonon, MP; Rueda, A; Hernandez, JJC.

SEOM clinical guidelines for the treatment of head and neck cancer (2017)

Clinical & Translational Oncology. 2018; 20(1): 75-83 Nº de citas: 24 [doi:10.1007/s12094-017-1776-1]

Ruiz-Pinto, S; Pita, G; Martin, M; Alonso-Gordoa, T; Barnes, DR; Alonso, MR; Herraez, B; Garcia-Miguel, P; Alonso, J; Perez-Martinez, A; Carton, AJ; Gutierrez-Larraya, F; Garcia-Saenz, JA; Benitez, J; Easton, DF; Patino-Garcia, A; Gonzalez-Neira, A.

Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients

BREAST CANCER RESEARCH AND TREATMENT. 2018; 167(1): 249-256 Nº de citas: 27 [doi:10.1007/s10549-017-4497-9]

Carles, J; Mendez, MJ; Pinto, A; Saez, MI; Arranz, JA; Maroto, P; Lopez-Criado, P; Mellado, B; Donas, JG; Hernando, S; Leon, L; del Alba, AG; Lainez, N; Esteban, E; Reynes, G; Perez-Gracia, JL; Germa, JR; Lopez-Brea, M; Perez-Valderrama, B; Moretones, C; Castellano, D.

Radium-223 international early access program: results from the Spanish subset

Future Oncology. 2018; 14(1): 41-50 Nº de citas: 4 [doi:10.2217/fon-2017-0297]

Martin, AM; Hidalgo, M; Alvarez, R; Arrazubi, V; Martinez-Galan, J; Salgado, M; Macarulla, T; Carrato, A.

From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer

Journal of Cancer. 2018; 9(11): 1978-1988 Nº de citas: 31 [doi:10.7150/jca.23716]

Castellano, D; Maroto, JP; Espinosa, E; Grande, E; Bolos, MV; Llinares, J; Esteban, E; del Alba, AG; Climent, MA; Arranz, JA; Mendez, MJ; Parra, EF; Anton-Aparicio, L; Bayona, C; Gallegos, I; Gallardo, E; Samaniego, L; Donas, JG.

Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies

Expert Opinion On Drug Safety. 2018; 17(6): 573-579 Nº de citas: 3 [doi:10.1080/14740338.2017.1330410]

Redondo, A; Bague, S; Bernabeu, D; Ortiz-Cruz, E; Valverde, C; Alvarez, R; Martinez-Trufero, J; Lopez-Martin, JA; Correa, R; Cruz, J; Lopez-Pousa, A; Santos, A; del Muro, XG; Martin-Broto, J.

Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS)

CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2017; 80(6): 1113-1131 Nº de citas: 47 [doi:10.1007/s00280-017-3436-0]

Martin, AJM; Adeva, J; Martinez-Galan, J; Reina, JJ; Hidalgo, M.

Pancreatic ductal adenocarcinoma: metastatic disease

Clinical & Translational Oncology. 2017; 19(12): 1423-1429 Nº de citas: 9 [doi:10.1007/s12094-017-1690-6]

Martin, M; Holmes, FA; Ejlertsen, B; Delaloge, S; Moy, B; Iwata, H; von Minckwitz, G; Chia, SKL; Mansi, J; Barrios, CH; Gnant, M; Tomasevic, Z; Denduluri, N; Separovic, R; Gokmen, E; Bashford, A; Borrego, MR; Kim, SB; Jakobsen, EH; Ciceniene, A; Inoue, K; Overkamp, F; Heijns, JB; Armstrong, AC; Link, JS; Abraham, A; Bryce, JR; Wong, A; Moran, S; Yao, B; Xu, F; Auerbach, A; Buyse, M; Chan, A; ExteNET Study Grp.

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

LANCET ONCOLOGY. 2017; 18(12): 1688-1700 Nº de citas: 508 [doi:10.1016/S1470-2045(17)30717-9]

Climent, MA; Perez-Valderrama, B; Mellado, B; Parra, EMF; Calvo, OF; de Olza, MO; Romay, LM; Anido, U; Domenech, M; Polo, SH; Arija, JAA; Caballero, C; Fita, MJJ; Castellano, D.

Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial

EUROPEAN JOURNAL OF CANCER. 2017; 87: 30-37 Nº de citas: 20 [doi:10.1016/j.ejca.2017.09.028]

Algarra, SM; Soriano, V; Fernandez-Morales, L; Berciano-Guerrero, MA; Mujika, K; Manzano, JL; Hernandez, TP; Soria, A; Rodriguez-Abreu, D; Arranz, EE; Martinez, JM; Marquez-Rodas, I; Rubio-Casadevall, J; Ortega, ME; Garcia, JMJ; Biurrun, MJL; Palacio, I; Artacho, MRD; Altozano, JP; Rubio, VEC; Garcia, A; Luna, P; Ballesteros, A; Fernandez, O; Martin, JAL; Berrocal, A; Arance, A.

Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study

MEDICINE. 2017; 96(52): Nº de citas: 9 [doi:10.1097/MD.0000000000009523]

van Krieken, JH; Kafatos, G; Bennett, J; Mineur, L; Tomasek, J; Rouleau, E; Fabian, P; De Maglio, G; Garcia-Alfonso, P; Aprile, G; Parkar, P; Downey, G; Demonty, G; Trojan, J.

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review

BMC CANCER. 2017; 17: Nº de citas: 8 [doi:10.1186/s12885-017-3740-4]

Weber, J; Mandala, M; Del Vecchio, M; Gogas, HJ; Arance, AM; Cowey, CL; Dalle, S; Schenker, M; Chiarion-Sileni, V; Marquez-Rodas, I; Grob, JJ; Butler, MO; Middleton, MR; Maio, M; Atkinson, V; Queirolo, P; Gonzalez, R; Kudchadkar, RR; Smylie, M; Meyer, N; Mortier, L; Atkins, MB; Long, GV; Bhatia, S; Lebbe, C; Rutkowski, P; Yokota, K; Yamazaki, N; Kim, TM; de Pril, V; Sabater, J; Qureshi, A; Larkin, J; Ascierto, PA; CheckMate 238 Collaborators.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

NEW ENGLAND JOURNAL OF MEDICINE. 2017; 377(19): 1824-1835 Nº de citas: 1889 [doi:10.1056/NEJMoa1709030]

Garrido, P; Aldaz, A; Calleja, MA; de Alava, E; Lamas, MJ; Martin, M; Matias-Guiu, X; Palacios, J; Vera, R.

Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: a position statement of SEOM, SEAP and SEFH

FARMACIA HOSPITALARIA. 2017; 41(6): 688-691 Nº de citas: 3

Alvarez, YE; Insignares, CA; Olea, MA; Barajas, O; Calderillo, G; Guaman, JCC; Caponero, R; Salazar, BAC; del Giglio, A; Araya, ARP; Villalobos-Valencia, R; Perez, AY; Delgado, NZ.

Cancer pain management: recommendations from a Latin-American experts panel

Future Oncology. 2017; 13(27): 2455-2472 Nº de citas: 2 [doi:10.2217/fon-2017-0288]

Long, GV; Weber, JS; Larkin, J; Atkinson, V; Grob, JJ; Schadendorf, D; Dummer, R; Robert, C; Marquez-Rodas, I; McNeil, C; Schmidt, H; Briscoe, K; Baurain, JF; Hodi, FS; Wolchok, JD.

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical Trials

JAMA Oncology. 2017; 3(11): 1511-1519 Nº de citas: 146 [doi:10.1001/jamaoncol.2017.1588]

Martin, M; Chacon, JI; Anton, A; Plazaola, A; Garcia-Martinez, E; Segui, MA; Sanchez-Rovira, P; Palacios, J; Calvo, L; Esteban, C; Espinosa, E; Barnadas, A; Batista, N; Guerrero, A; Munoz, M; Romio, E; Rodriguez-Martin, C; Caballero, R; Casas, MI; Rojo, F; Carrasco, E; Antolin, S.

Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis

ONCOLOGIST. 2017; 22(11): 1301-1308 Nº de citas: 16 [doi:10.1634/theoncologist.2017-0052]

Marquez-Rodas, I; Pollan, M; Escudero, MJ; Ruiz, A; Martin, M; Santaballa, A; del Prado, PM; Batista, N; Andres, R; Anton, A; Llombart, A; Aramburu, AF; Adrover, E; Gonzalez, S; Segui, MA; Calvo, L; Lizon, J; Lescure, AR; Cajal, TRY; Llort, G; Jara, C; Carrasco, E; Lopez-Tarruella, S.

Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "ElA Alamo III" retrospective study

PLoS One. 2017; 12(10): [doi:10.1371/journal.pone.0184181]

Wolchok, JD; Chiarion-Sileni, V; Gonzalez, R; Rutkowski, P; Grob, JJ; Cowey, CL; Lao, CD; Wagstaff, J; Schadendorf, D; Ferrucci, PF; Smylie, M; Dummer, R; Hill, A; Hogg, D; Haanen, J; Carlino, MS; Bechter, O; Maio, M; Marquez-Rodas, I; Guidoboni, M; McArthur, G; Lebbe, C; Ascierto, PA; Long, GV; Cebon, J; Sosman, J; Postow, MA; Callahan, MK; Walker, D; Rollin, L; Bhore, R; Hodi, FS; Larkin, J.

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

NEW ENGLAND JOURNAL OF MEDICINE. 2017; 377(14): 1345-1356 Nº de citas: 2977 [doi:10.1056/NEJMoa1709684]